At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Acalabrutinibdrug
Likely dose
Acalabrutinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Preventing Life-Threatening Allergic Reactions With Acalabrutinib, an FDA-Approved Bruton's Tyrosine Kinase Inhibitor
In Brief
A Phase 2 clinical trial evaluating Acalabrutinib for Food Allergy and Food Allergy Peanut. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food challenge in food-allergic adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFood Allergy, Food Allergy Peanut
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartDec 2021
Primary CompletionDec 2022
Study CompletionDec 2022
TodayJul 2026
First PostedSep 9, 2021
Enrollment StartDec 16, 2021
Primary CompletionDec 8, 2022
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 4.8 years ago
Interventions
Acalabrutinibdrug
100 mg oral capsule